Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia

Haematologica

Volumn 99, Issue 10, 2014, Pages e179-e181

  Müller Thomas, Catharina ^a   Rudelius, Martina ^b   Rondak, Ina Christine ^c   Haferlach, Torsten ^d   Schanz, Julie ^e   Huberle, Christina ^a   Schmidt, Burkhard ^f   Blaser, Rainer ^c   Kremer, Marcus ^g   Peschel, Christian ^a,h   Germing, Ulrich ⁱ   Platzbecker, Uwe ^h,j   Götze, Katharina ^a,h  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d MLL MUNICH LEUKEMIA LABORATORY   (Germany)

^e UNIVERSITY OF GÖTTINGEN   (Germany)

^f Hematology and Oncology Practice   (Germany)

^g Institute of Pathology   (Germany)

^h GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

ⁱ HEINRICH HEINE UNIVERSITY   (Germany)

^j DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

more..

Author keywords

Azacitidine; MDS; p53 expression; TP53 mutations

Indexed keywords

ASXL1 PROTEIN; AZACITIDINE; LENALIDOMIDE; PEPTIDES AND PROTEINS; PROTEIN P53; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; BONE MARROW BIOPSY; CHROMOSOME ABERRATION; FRAMESHIFT MUTATION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KARYOTYPE; LETTER; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NONSENSE MUTATION; OVERALL SURVIVAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; COMPLICATION; GENE EXPRESSION; GENETICS; LEUKEMIA, MYELOID, ACUTE; MORTALITY; MYELODYSPLASTIC SYNDROMES; TREATMENT OUTCOME;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; GENE EXPRESSION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84907504886     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.104760     Document Type: Letter

References (15)

1. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. Clinical Effect of Point Mutations in Myelodysplastic Syndromes. N Engl J Med. 2011;364(26):2496-506.
2. Haferlach T, Nagata Y, Grossmann V, Okuno Y, Bacher U, Nagae G, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014;28(2)241-7.
3. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616-27.
4. Thol F, Friesen I, Damm F, Yun H, Weissinger EM, Krauter J, et al. Prognostic Significance of ASXL1 Mutations in Patients With Myelodysplastic Syndromes. J Clin Oncol. 2011;29(18):2499-506.
5. Kita-Sasai Y, Horiike S, Misawa S, Kaneko H, Kobayashi M, Nakao M, et al. International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome. Br J Haematol. 2001;115(2):309-12.
6. Kulasekararaj AG, Smith AE, Mian SA, Mohamedali AM, Krishnamurthy P, Lea NC, et al. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol. 2013; 160(5):660-72.
7. Jädersten M, Saft L, Smith A, Kulasekararaj A, Pomplun S, Göhring G, et al. TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression. J Clin Oncol. 2011;29(15):1971-9.
8. Saft L, Karimi M, Ghaderi M, Matolcsy A, Mufti GJ, Kulasekararaj A, et al. P53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q). Haematologica. 2014;99(6):1041-9.
9. Iwasaki T, Murakami M, Sugisaki C, Sobue S, Ohashi H, Asano H, et al. Characterization of myelodysplastic syndrome and aplastic anemia by immunostaining of p53 and hemoglobin F and karyotype analysis: Differential diagnosis between refractory anemia and aplastic anemia. Pathol Int. 2008;58(6):353-60.
10. Schanz J, Tüchler H, Solé F, Mallo M, Luno E, Cervera J, et al. New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge. J Clin Oncol. 2012;30(8):820-9.
11. Breems DA, Van Putten WLJ, De Greef GE, Van Zelderen-Bhola SL, Gerssen-Schoorl KBJ, Mellink CHM, et al. Monosomal Karyotype in Acute Myeloid Leukemia: A Better Indicator of Poor Prognosis Than a Complex Karyotype. J Clin Oncol. 2008;26(29):4791-7.
12. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419-25.
13. Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomized, open-label phase III study. Lancet Oncol. 2009;10:223-32.
14. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28(6):622-9.
15. Platzbecker U, Braulke F, Kündgen A, Götze K, Bug G, Schonefeldt C, et al. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study. Leukemia. 2013;27(6):1403-7.